The immunology of hepatocellular carcinoma

By M. Ringelhan, D. Pfister, T. O’Connor, E. Pikarsky, M. Heikenwalder. Nature Immunology, 2018

731 citations recorded by the source corpus.

Subfields: Cell Biology, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/7417d6bfdf1e0eff0d5b17f7f5f72743690c1aaf

Citations in the corpus

• Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020, neutral): “Hypothyroidism 25 (25) 11 (11) 14 (14) 0 Palmar-plantar erythrodysesthesia syndrome 23 (23) 13 (13) 9 (9) 1 (1) Weight decreased 22 (22) 8 (8) 11 (11) 3 (3) Dysphonia 21 (21) 19 (19) 1 (1) 1 (1)”